Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.32 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27202070 | 0.77 | THRB (0.33) | KDM4ELMNAMEN1KMT2A | |
| SCHEMBL3914430 | 0.75 | MKNK1 (0.41) | KDM4ELMNAADORA2AADORA1 | |
| SCHEMBL30940528 | 0.74 | TYK2 (0.45) | KDM4ELMNAMEN1KMT2A | |
| SCHEMBL1403852 | 0.73 | SIRT3 (0.46) | LRRK2KDM4ELMNAADORA3PKM | |
| SCHEMBL27202064 | 0.72 | CA2 (0.31) | — | |
| SCHEMBL31686263 | 0.71 | TDP1 (0.37) | LRRK2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL30591940 | 0.71 | MAP2K3 (0.44) | LRRK2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL3145246 | 0.71 | MAP2K3 (0.44) | LRRK2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL19691158 | 0.71 | KMT2A (0.37) | KDM4EMEN1KMT2A | |
| SCHEMBL28309038 | 0.71 | SIRT3 (0.38) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-117321043-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2023-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | LRRK2 4742/4885CSF1R 4249/4885PDGFRA 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.